Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Cancer Stroma-Targeting Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD90/THY1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD90/THY1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD90 Products |
| Gene Delivery | CD90/THY1 Lentivirus Particles Full-length ORF with GPI-anchor signal for stable cell line construction. High titer (>10^8 TU/ml). |
View CD90 Products |
| Benchmark Ab | Anti-CD90 (Clone 5E10) Recombinant Antibody Positive control for flow cytometry and binding assays. Sequence verified. |
View CD90 Products |
| Validator | CD90/THY1 siRNA Set (3 targets + scramble) For knockdown verification and specificity controls. |
View CD90 Products |
| Related Target A | CD105 (Endoglin) Complementary MSC/CAF marker for dual-targeting strategies and fibrosis indication expansion. |
View CD105 Products |
| Related Target B | PDGFRβ Key fibroblast activation marker; co-expression analysis with CD90 for stroma heterogeneity studies. |
View PDGFRB Products |
| Related Target C | FAP (Fibroblast Activation Protein-α) Alternative CAF target; cross-comparison for epitope specificity and therapeutic window optimization. |
View FAP Products |
| Related Target D | CD44 Synergistic target for cancer stem cell (CSC) eradication and metastasis prevention. |
View CD44 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPI-Anchor Protein Folding & Stability | ECD-Fc construct with optimized cleavage site; Sequence-verified native conformation; High-purity (>95%) monomeric form by SEC-MALS |
| Cross-species Cyno/Mouse/Human Translation | Ortholog protein panel available (Human, Cyno, Mouse) with >95% purity; Conserved epitope mapping support |
| Stromal Cell Internalization (ADC Development) | Cell-based internalization assay ready; Lentivirus pre-made particles for HEK293/CD90+ stable lines; pH-sensitive dye compatible |
| Specificity vs. MSC Populations | siRNA validation set included; Knockdown controls for distinguishing cancer-associated fibroblasts from mesenchymal stem cells |
| Lack of Assay Controls | Research-grade benchmark antibodies and validated siRNA included for assay standardization |
| False Positives / Off-target Binding | Validated siRNA included for specificity checks; Clinical benchmark antibodies for comparison |
Live CD90/THY1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD90/THY1 is experiencing renewed interest as a strategy to modulate the tumor microenvironment and treat fibrotic diseases. As a GPI-anchored glycoprotein expressed on cancer-associated fibroblasts (CAFs), mesenchymal stem cells, and subsets of cancer stem cells, CD90 represents an accessible extracellular target for antibody-based modalities. The current pipeline has shifted from simple MSC identification markers toward sophisticated stroma-depleting strategies, with particular momentum in idiopathic pulmonary fibrosis (IPF), solid tumors (e.g., PDAC, HCC, glioblastoma), and liver fibrosis. Emerging modalities include Antibody-Drug Conjugates (ADCs), CAR-T/NK cell therapies, bispecifics, and depleting monoclonal antibodies. The next wave of R&D is targeting highly specific epitope binding to circumvent on-target, off-tumor toxicity on normal stem cells and endothelial tissues, while combination strategies with checkpoint inhibitors and anti-fibrotic small molecules are being explored.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotechs, Academic Labs | Solid Tumors (PDAC, HCC, Breast), Liver Fibrosis | Internalization Assay: high-purity CD90 ECD-Fc for binding; Lentivirus for cell surface presentation |
| CAR-T/NK | Cell Therapy Focused Startups, Specialized Oncology Clinics | Leukemia, Solid Tumors (Glioblastoma, Mesothelioma) | Cell Line Construction: Lentivirus for stable CD90+ target cells; Epitope specificity with sequence-verified domains |
| Bispecific | Immuno-oncology Leaders, Mid-Cap Biopharma | Tumor Stroma Modulation, Fibrosis | Heterodimer Validation: Dual-target with FAP or PDGFRβ; High-purity protein pairs |
| Depleting mAb | Mid-Size Pharma, Established Pharma | IPF, NASH, Scleroderma | Cross-reactivity Panel: Human/Mouse/Cyno ortholog proteins for translational pharmacology |
| Biologic / Fusion Protein | Preclinical Programs | Dermal, Ocular Fibrosis | Cross-reactive protein panel; Pharmacology/toxicology bridging studies |
Molecular Characteristics & Assay Design Considerations
CD90/THY1 is a 25-37 kDa GPI-anchored glycoprotein with a heavily glycosylated extracellular Ig-like V-type domain (UniProt P04216). This molecular architecture presents specific challenges for drug development:
- GPI-Anchor Dynamics: Unlike transmembrane proteins, CD90 associates with lipid rafts and exhibits rapid lateral diffusion. For cell-based assays, lentivirus-mediated stable expression in HEK293 cells preserves this native membrane organization.
- Glycosylation Patterns: Extensive N-glycosylation affects antibody binding epitopes. TarMart's HEK293-expressed proteins ensure mammalian glycosylation patterns critical for antibody screening.
- Soluble Shedding: CD90 can be shed from the membrane via phospholipase activity. Assay designs must account for soluble vs. membrane-bound discrimination using our paired antibody/antigen systems.
- Internalization via Lipid Rafts: For ADC development, internalization efficiency varies between quiescent MSCs and activated CAFs. Lentivirus-based stable cell lines enable high-throughput internalization screening under physiologically relevant expression levels, using pH-sensitive dye compatible methods.
For robust assay design, we recommend using high-purity ECD-Fc fusion proteins for binding and epitope mapping, lentivirus particles for cell surface presentation, and siRNA sets for specificity validation. Cross-species ortholog panels (human/mouse/cyno) enable translational pharmacology and toxicity assessments.